The Role of Long Non-coding RNA (NKILA and LINC00993) as Tumour Biomarkers in Breast Cancer

Abstract

Abstract Background Breast cancer) BC) is the most frequent cancer among women and the second most common cause of cancer deaths worldwide. Long non-coding RNAs (NKILA and LINC00993) are downregulated in BC and can have potential use as a novel tumor biomarker. Aim of the work: To investigate the Long non-coding RNA (NKILA and LINC00993) and cytokines (NF-KB and CXCL-1) as potential biomarkers in breast cancer. Subjects and methods: This case-control study included sixty-four pairs of surgically resected human breast cancer tissues and adjacent breast tissues. Expressions of LncRNAs (NKILA, LINC00993) and (NFκB, CXCL1) cytokines were detected using real-time quantitative polymerase chain reaction (qPCR) analysis, Results There was a significant decrease in LncRNAs (NKILA, LINC00993) levels in tumor tissue compared to normal tissue (P < 0.001). Also, there was a significant increase in NF-KP and CXCL1 levels in tumor tissue compared to normal tissue (P < 0.001). ROC curve analysis indicated that the LncRNAs (NKILA, LINC00993) expression levels could be considered a promising marker for the diagnosis of breast cancer patients with a sensitivity (90.6%, 92.2% respectively). Also, cytokines (NF-KB and CXCL-1) expression levels could be considered a promising marker for the diagnosis of breast cancer patients with a sensitivity and specificity of 87.5%, 89.1% respectively). Conclusion These findings suggest that LncRNAs (NKILA, LINC00993) and cytokines (NF-KB and CXCL-1) can be used as novel biomarkers for breast cancer.